NTRA News and Press, Natera Inc. From 11/08/22

Natera press release ( NASDAQ: NTRA ): Q3 GAAP EPS of -$1.25 beats by $0.20 . Revenue of $210.64M (+33.2% Y/Y) beats by $3.98M. Product revenues grew 29.8% over the same period. Outlook: 2022 revenue guidance raised to $810 million – $830 million, up...

The following slide deck was published by Natera, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Natera, Inc. 2022 Q3 - Results - Earnings Call Presentation

Natera Reports Third Quarter 2022 Financial Results PR Newswire AUSTIN, Texas , Nov. 8, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30...

Summary GH's aberrant trading pattern after its Q3 earnings release on Friday mirrors two conflicting trends arising from the company's unique market position. A new paradigm in the gene testing market is now emphasizing clearer paths to profitability, contradicting GH's spending ...

Summary VCYT exceeded investors' expectations, coupling solid revenue growth with improved profitability. Unique international exposure offers revenue tailwinds as Europe accelerates gene diagnostic testing adoption. In view of the probability that the political and regulatory...

Natera ( NASDAQ: NTRA ) said Wednesday it was awarded a nationwide contract by the U.S. Dept. of Veterans Affairs National Precision Oncology Program, effective Sept. 15. The contract is for minimal residual disease and monitoring services with Natera's ( NTRA )&#...

Natera Awarded National MRD Testing Contract by the U.S. Department of Veterans Affairs PR Newswire AUSTIN, Texas , Nov. 2, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it was...

Natera to Participate in Credit Suisse 31st Annual Healthcare Conference PR Newswire AUSTIN, Texas , Nov. 1, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Steve Chapman , chief...

Natera to Report its Third Quarter 2022 Results on November 8th PR Newswire AUSTIN, Texas , Nov. 1, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it will release results for its third q...

Summary The FDA is preparing to extend its regulatory arm over LDTs. The potential for negative regulatory intervention puts OCX's strategy into serious question. OCX must navigate the new regulations and the limited resources that come with being a small-cap company while try...